Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback